Combination Lucentis and Ocular Photodynamic Therapy With Visudyne, With Evaluation-based Retreatment
Status:
Completed
Trial end date:
2009-10-01
Target enrollment:
Participant gender:
Summary
This is a one-year, randomized, single-center open-label pilot study of the safety and
efficacy of combination ranibizumab and PDT for AMD. Eligible subjects will be randomized to
either combination treatment, or ranibizumab monotherapy (control group).
The combination treatment group will receive ranibizumab, followed 1 week later by
verteporfin PDT. Additional treatments will be based on evidence of active disease
(subretinal fluid on OCT or leakage on FA): repeat ranibizumab injections will be allowed
monthly, and repeat PDT will be allowed every 3 months.
The control group will receive "standard-of-care" ranibizumab monotherapy according to the
protocol currently followed by most retinal specialists. Ranibizumab injections will be given
at baseline and months one and two. Additional injections will be given at each monthly visit
at which there is evidence of active disease by visual acuity, OCT and FA criteria.